As a proof-of-concept, the most tempting approach in treating SMA is to upregulate SMN2, retaining in all patients, to function as the missing SMN1, either by activating the SMN2 gene or by modulation of SMN2 splicing [1,3,6,30]. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.